A5054210888- CAR-T cell therapy research
- Lymphoma Diagnosis and Treatment
- Biosimilars and Bioanalytical Methods
- Immunotherapy and Immune Responses
- Integrated Circuits and Semiconductor Failure Analysis
- Viral Infectious Diseases and Gene Expression in Insects
- Immune Cell Function and Interaction
- Virus-based gene therapy research
- Advancements in Semiconductor Devices and Circuit Design
- Biomedical Ethics and Regulation
- Hematopoietic Stem Cell Transplantation
- Chronic Lymphocytic Leukemia Research
- CNS Lymphoma Diagnosis and Treatment
- Glioma Diagnosis and Treatment
- Neutropenia and Cancer Infections
- Silicon Carbide Semiconductor Technologies
- Monoclonal and Polyclonal Antibodies Research
- Acute Myeloid Leukemia Research
- Multiple Myeloma Research and Treatments
- T-cell and B-cell Immunology
- Acute Lymphoblastic Leukemia research
- Cancer Immunotherapy and Biomarkers
- Protein Degradation and Inhibitors
- Brain Metastases and Treatment
- Nanowire Synthesis and Applications
Ludwig-Maximilians-Universität München
2020-2025
German Cancer Research Center
2021-2025
LMU Klinikum
2020-2025
Memorial Sloan Kettering Cancer Center
2024-2025
Heidelberg University
2021-2025
Cancer Research Center
2025
Deutschen Konsortium für Translationale Krebsforschung
2021-2025
University Hospital Heidelberg
2024-2025
München Klinik
2023
Huawei German Research Center
2023
T-cell-recruiting bispecific molecule therapy has yielded promising results in patients with hematologic malignancies; however, resistance and subsequent relapse remains a major challenge. T-cell exhaustion induced by persistent antigen stimulation or tonic receptor signaling been reported to compromise outcomes of T-cell-based immunotherapies. The impact continuous exposure bispecifics on function, poorly understood. In relapsed/refractory B-cell precursor acute lymphoblastic leukemia...
<h3>Background</h3> CD19-directed chimeric antigen receptor T-cell therapy (CAR-T) represents a promising treatment modality for an increasing number of B-cell malignancies. However, prolonged cytopenias and infections substantially contribute to the toxicity burden CAR-T. The recently developed CAR-HEMATOTOX (HT) score—composed five pre-lymphodepletion variables (eg, absolute neutrophil count, platelet hemoglobin, C-reactive protein, ferritin)—enables risk stratification hematological...
Approximately 30%-40% of patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) infused CD19-targeted chimeric antigen receptor (CAR) T cells achieve durable responses. Consensus guidelines suggest avoiding bendamustine before apheresis, but specific data in this setting are lacking. We report distinct outcomes after CAR T-cell therapy according to previous exposure.
Abstract Background BCMA-directed CAR T-cell therapy (CAR-T) has altered the treatment landscape of relapsed/refractory (r/r) multiple myeloma, but is hampered by unique side effects that can lengthen hospital stays and increase morbidity. Hematological toxicity (e.g. profound prolonged cytopenias) represents most common grade ≥ 3 predispose for severe infectious complications. Here, we examined utility CAR-HEMATOTOX (HT) score to predict survival outcomes in patients receiving...
Abstract Cytopenias represent the most common side effect of CAR T-cell therapy (CAR-T) and can predispose for severe infectious complications. Current grading systems, such as Common Terminology Criteria Adverse Events (CTCAE), neither reflect unique quality post–CAR-T neutrophil recovery, nor do they inherent risk infections due to protracted neutropenia. For this reason, a novel EHA/EBMT consensus was recently developed Immune Effector Cell-Associated HematoToxicity (ICAHT). In...
CD19 CAR T-cells represent a practice-changing treatment modality for advanced B-cell malignancies. However, refractory cytopenias have emerged as potentially life-threatening complication that can persist long after lymphodepleting chemotherapy. Whether stem cell rescue is feasible and efficacious CAR-T has not been addressed. In this retrospective multi-center study, we describe clinical characteristics outcomes of 13 patients with hyporegenerative bone marrow (BM) failure CAR-T, which...
Hematological toxicity represents the most common grade ≥3 after chimeric antigen receptor (CAR) T-cell therapy. However, its underlying pathophysiology is incompletely understood and grading management remains ill-defined. To inform forthcoming European Hematology Association/European Society for Blood Marrow Transplantation (EHA/EBMT) guidelines on of "immune effector cell-associated hematotoxicity" (ICAHT), we undertook a survey experienced clinicians using an online focusing (1) grading,...
Prolonged cytopenias after chimeric antigen receptor (CAR) T cell therapy are a significant clinical problem and the underlying pathophysiology remains poorly understood. Here, we investigated how expansion dynamics serum proteomics affect neutrophil recovery phenotypes CD19-directed CAR therapy. Survival favored patients with "intermittent" (e.g., recurrent dips) compared to either "quick" or "aplastic" recovery. While intermittent displayed increased expansion, aplastic exhibited an...
A subset of patients with diffuse large B-cell lymphoma (DLBCL) treated CD19 chimeric antigen receptor (CAR) T-cell therapy have poor clinical outcomes. We report serum proteins associated severe immune-mediated toxicities and inferior responses in 146 DLBCL axicabtagene ciloleucel. develop a simple stratification based on pre-lymphodepletion C reactive protein (CRP) ferritin to classify into low-, intermediate-, high-risk groups. observe that the category were more likely grade ≥3 had...
This cohort study assesses the increase in second primary malignant neoplasms and T-cell neoplasm cases associated with chimeric antigen receptor–T cells.
Abstract Background Prolonged myelosuppression following CD19-directed CAR T-cell transfusion represents an important, yet underreported, adverse event. The resulting neutropenia and multifactorial immunosuppression can facilitate severe infectious complications. Case presentation We describe the clinical course of a 59-year-old patient with relapsed/refractory DLBCL who received Axicabtagene-Ciloleucel (Axi-cel). developed ASTCT grade I CRS IV ICANS, necessitating admission to neurological...
Secondary CNS involvement in systemic B-cell lymphoma (SCNSL) is difficult to treat and displays dismal clinical outcomes. Chimeric antigen receptor (CAR) T cells emerged as a powerful treatment for lymphoma. We aimed evaluate whether CAR also represent safe effective therapy SCNSL.We retrospectively searched our institutional database patients with SCNSL treated CD19-directed cells.We identified 10 cases, including 7 intraparenchymal lesions 3 leptomeningeal disease. staging at 1 month...
Abstract CD19‐directed CAR T‐cell therapy with brexucabtagene autoleucel (brexu‐cel) has substantially improved treatment outcomes for patients relapsed/refractory mantle cell lymphoma (r/r MCL). Prolonged cytopenias and infections represent common clinically relevant side effects. In this multicenter observational study, we describe in 103 r/r MCL receiving brexu‐cel. Furthermore, report associations between the baseline CAR‐HEMATOTOX (HT) score toxicity events, non‐relapse mortality (NRM),...